Gemphire Therapeutics Inc (GEMP) Stock Price, Forecast & Analysis

NASDAQ:GEMP

0.3
0 (-0.37%)
At close: Dec 30, 2019
0.3
0 (0%)
After Hours: 12/30/2019, 9:09:12 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

GEMP Key Statistics, Chart & Performance

Key Statistics
Market Cap4.46M
Revenue(TTM)N/A
Net Income(TTM)-13.81M
Shares14.87M
Float10.80M
52 Week High1.49
52 Week Low0.24
Yearly Dividend0
Dividend Yield0%
EPS(TTM)-1.16
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
GEMP short term performance overview.The bars show the price performance of GEMP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

GEMP long term performance overview.The bars show the price performance of GEMP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of GEMP is 0.3 null. In the past month the price decreased by -16.43%. In the past year, price decreased by -64.07%.

Gemphire Therapeutics Inc / GEMP Daily stock chart

GEMP Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
GEMP Full Technical Analysis Report

GEMP Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to GEMP. GEMP may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GEMP Full Fundamental Analysis Report

GEMP Financial Highlights

Over the last trailing twelve months GEMP reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 53.6% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -674.17%
ROE N/A
Debt/Equity -6.24
Chartmill High Growth Momentum
EPS Q2Q%57.45%
Sales Q2Q%N/A
EPS 1Y (TTM)53.6%
Revenue 1Y (TTM)N/A
GEMP financials

GEMP Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next Y-46.2%
Revenue Next YearN/A
GEMP Analyst EstimatesGEMP Analyst Ratings

GEMP Ownership

Ownership
Inst Owners17.53%
Ins Owners25.01%
Short Float %N/A
Short RatioN/A
GEMP Ownership

About GEMP

Company Profile

Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company's product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan.

Company Info

Gemphire Therapeutics Inc

17199 N. LAUREL PARK DRIVE SUITE 401

LIVONIA MI 48152

CEO: Steven Gullans

Phone: 734-245-1700

Gemphire Therapeutics Inc / GEMP FAQ

What does GEMP do?

Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company's product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan.


What is the current price of GEMP stock?

The current stock price of GEMP is 0.3 null. The price decreased by -0.37% in the last trading session.


Does Gemphire Therapeutics Inc pay dividends?

GEMP does not pay a dividend.


What is the ChartMill technical and fundamental rating of GEMP stock?

GEMP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Would investing in Gemphire Therapeutics Inc be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GEMP.


Who owns Gemphire Therapeutics Inc?

You can find the ownership structure of Gemphire Therapeutics Inc (GEMP) on the Ownership tab.